PHOENIX, Ariz. Feb. 11, 2009 The Van Andel Research Institute (VARI) and the Translational Genomics Research Institute (TGen) will forge a strategic alliance that will enable both to maximize their worldwide contributions to science and health.
The non-profit researcher institutes jointly announced today the initiation of an "alliance and affiliation agreement.''
The partnership between Grand Rapids, Mich.-based VARI and Phoenix, Ariz.-based TGen will enable both institutes to speed up their mutual goals of moving research discoveries about cancer and other debilitating medical conditions as quickly as possible from laboratories to patient care.
VARI is the research arm of the Van Andel Institute (VAI), established in 1996 as a philanthropic research and educational organization by the late Jay and Betty Van Andel.
"We are excited to welcome TGen as they combine forces with us in our mission to conquer cancer and human disease,'' said VAI Chairman and CEO David Van Andel. "This alliance demonstrates that VARI and TGen are at the forefront of redefining a borderless, collaborative, national and international scientific community that transcends geographical limitations."
The alliance combines the groundbreaking basic research expertise of VARI with the cutting-edge translational genomics and analysis of TGen.
"Combining many of the scientific, educational, financial and business potentials of TGen and VARI will advance the research of both institutions and enhance the economic development of both Arizona and Western Michigan,'' said Dr. Jeffrey Trent, President and Scientific Director of TGen since its founding in 2002.
"This alliance will elevate both organizations in the world of scientific research," said Dr. Trent, who will retain his roles at TGen, but upon implementation of the agreement also will become President and Research Director of VARI.
Dr. Trent will replace Dr. George
|Contact: Steve Yozwiak, TGen Senior Science Writer|
The Translational Genomics Research Institute